PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Recruiting · NCT00710177 · Observational (researchers observe without assigning treatment) · Lead sponsor: Medical College of Wisconsin
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
Who can take part
Age range
Up to 12 Months
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.
Exclusion criteria
- Patients will be excluded if they are diagnosed with lethal congenital anomalies
- structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
- structural gastrointestinal tract abnormality that could interfere with meconium passage
- congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia
Where it is running
1 location listed across 1 US state.
- Children's Wisconsin - Milwaukee, Wisconsin, United States